About Our Ongoing NSCLC Trial
Trial Design
We continue to advance our randomized, double-blind, placebo-controlled Phase 1b clinical trial of ALRN-6924 for the prevention of chemotherapy-induced side effects in patients with advanced p53-mutated NSCLC.
We plan to enroll a total of 60 patients with advanced p53-mutated NSCLC undergoing treatment with first-line carboplatin plus pemetrexed with or without immune checkpoint inhibitors. Patients will be randomized 1:1 to receive carboplatin/pemetrexed plus 0.3 mg/kg ALRN-6924 or placebo for at least four 21-day treatment cycles.
Upcoming Data Readouts
Our planned data readouts include interim results on 20 patients in 2Q 2022, and topline results on 60 patients in 4Q 2022.
More Information
Please visit the NSCLC trial listing on clinicaltrials.gov.